Pantethine reduces plasma cholesterol and the severity of arterial lesions in experimental hypercholesterolemic rabbits.
Pantethine (P), a coenzyme A precursor, was administered to cholesterol-fed rabbits (0.5% cholesterol diet + 1% pantethine) for 90 days. At the end of treatment, plasma total cholesterol levels were reduced 64.7% and the HDL/total cholesterol ratio increased in P-treated animals; a significant rise of the apo A-I/A-II ratio was detected in HDL. VLDL lipid and protein levels were, on the other hand, reduced by P. The cholesterol-ester content of both liver and aortic tissues was not significantly affected by P. Although the total aortic area with evident plaques was reduced only 18.2%, the microscopical examination of sections from the major vessels of P-treated animals, showed a reduction in the severity of lesions, both in the aorta and in the coronary arteries. These findings suggest that P, in addition to significantly lowering plasma cholesterol levels in rabbits on an experimental diet, may modify lipid deposition in major arteries, possibly by affecting lipoprotein composition and/or exerting an arterial protective effect.
D000818:Animals; D001012:Aorta, Abdominal / Q000473:pathology; D016632:Apolipoprotein A-I; D016633:Apolipoprotein A-II; D001054:Apolipoproteins A / Q000097:blood; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D008076:Cholesterol, HDL / Q000097:blood; D003331:Coronary Vessels / Q000473:pathology; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D007525:Isoelectric Focusing; D008075:Lipoproteins, HDL / Q000097:blood; D008297:Male; D010204:Pantetheine / Q000031:analogs & derivatives / Q000627:therapeutic use*; D011817:Rabbits; D013438:Sulfhydryl Compounds / Q000627:therapeutic use*
D016632:Apolipoprotein A-I; D016633:Apolipoprotein A-II; D001054:Apolipoproteins A; D002791:Cholesterol, Dietary; D008076:Cholesterol, HDL; D008075:Lipoproteins, HDL; D013438:Sulfhydryl Compounds; D010204:Pantetheine; C005425:pantethine